



M Pless

Contact

M Pless

Publications (13)

Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali P, Ceresoli G, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalajt L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. *ESMO Open* 2022; 7:100446.

König D, Scharl S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild S, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet E, Hayoz S, Thierstein S, Betticher D, Ris H, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. *ESMO Open* 2022; 7:100455.

Soo R, Han J, Dafni U, Cho B, Yeo C, Nadal E, Carcereny E, de Castro J, Sala M, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. *Ann Oncol* 2021; 33:181-192.

Glatzer M, Pless M, Pederiva S, Pestalozzi B, Berger M, Inauen R, Winterhalder R, Montemurro M, Horber D, Putora P. Choice of first line systemic treatment in pancreatic cancer among national experts. *Pancreatology* 2020; 20:686-690.

Metaxas Y, von Moos R, Rauch D, Appenzeller C, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G, Zucali P, Pless M, Grosso F, Eboulet E, Früh M, Swiss Group for Clinical Cancer Research (SAKK). Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). *Ann Oncol* 2020; 31:495-500.

Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. *Lung Cancer* 2019; 130:149-155.

Früh M, Ris H, Xyrafas A, Peters S, Mirimanoff R, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. *Ann Oncol* 2016; 27:1971-3.

Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh M, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. *Ann Oncol* 2015; 27:281-6.

Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). *Lung Cancer* 2014; 85:306-13.

Strebel R, Winterhalder R, Morant R, Pless M, U H, Fehr M, Gillessen S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. *Support Care Cancer* 2013; 21:2327-33.

Uster A, Rühlin M, Rüfenacht U, Pless M, Siano M, Imoberdorf R, Ballmer p. Individuelle Ernährungsberatung bewirkt eine signifikante Steigerung der Energie- und Eiweisszufuhr bei unterernährten, ambulanten Krebspatienten: Eine kontrollierte, randomisierte Studie. Ernährung 2012

Pless M, Gambazzi F, Stillhart P, Lieb T, Brutsche M. Induction chemotherapy followed by parenchyma-sparing surgery in medically inoperable NSCLC-results of a feasibility study. Lung cancer (Amsterdam, Netherlands) 2008; 62:228-35.

Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer 2006; 94:1099-106.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch